This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ashwood, T.J. Articles by McCreadie, R.G. Search for Related Content PubMed Articles by Ashwood, T.J. Articles by McCreadie, R.G. Social Bookmarking                         What's this?

An open study of remoxipride in the long-term treatment of schizophrenia-

Astra Clinical Research Unit, 10 York Place, Edinburgh EHI 3EP

C. Hallstrom

Charing Cross Hospital, Fulham Palace Road, London W6 8RF

D.J. King

Department of Therapeutics and Pharmacology, Queens University of Belfast, Belfast BT9 7BL

M.G. Livingston

Gartnavel Royal Hospital, University Department, Psychological Medicine, Glasgow G12 OXH

R.G. McCreadie

Department of Clinical Research, Crichton Royal Hospital, Dumfries DG1 4TG, UK

An open non-comparative multicentre study was carried out to evaluate the safety and tolerability of remoxipride over a treatment period of 12 months. The efficacy of the drug in controlling psychotic symptoms was also monitored. Eighty-five men and women aged 18-69 who met the Research Diagnostic Criteria for schizophrenia were entered into the study and after withdrawal of previous antipsychotic medication, treated orally with remoxipride 75-300 mg b.i.d. The treatment was well tolerated and most of the adverse symptoms reported were reduced in incidence at the last rating compared to baseline. Sleep problems (insomnia and increased sleep) and increased thirst showed an increase in incidence during treatment. The incidence of extrapyramidal side effects was low and less than at baseline; there was no evidence that remoxipride produced an increase in abnormal involuntary movements, the median weight of the group did not alter and remoxipride produced no significant effect on cardiovascular, clinical chemistry and haematology variables. It appeared effective in controlling psychotic symptoms and produced some improvement on over one third of the patients despite the fact that the majority of patients entered were not in a productive phase of their illness. The results indicate that remoxipride will be well tolerated and effective when given for the maintenance treatment of schizophrenia.

Key Words: antipsychotic • clinical trial • dopamine D-2 receptor • neuroleptic • remoxipride • schizophrenia

Journal of Psychopharmacology, Vol. 6, No. 4, 519-525 (1992)
DOI: 10.1177/026988119200600408


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?